T1	Measurement 0 19	Response assessment
T2	Value 23 45	complete response (CR)
T3	Value 47 68	partial response (PR)
T4	Value 70 94	long stable disease (SD)
T5	Temporal 95 108	for >3 months
*	OR T3 T4 T2
T6	Scope 23 94	complete response (CR), partial response (PR), long stable disease (SD)
R1	Has_scope Arg1:T1 Arg2:T6	
R2	Has_temporal Arg1:T6 Arg2:T5	
T7	Qualifier 116 122	cancer
T8	Procedure 123 146	immunotherapy treatment
R3	Has_qualifier Arg1:T8 Arg2:T7	
T9	Condition 151 168	metastatic cancer
T10	Condition 172 196	hematologic malignancies
T11	Procedure 214 226	marketed CPI
T12	Observation 238 291	participation in a Roche/Genentech CPI clinical trial
*	OR T11 T12
*	OR T9 T10
T13	Scope 151 196	metastatic cancer or hematologic malignancies
R4	Has_scope Arg1:T8 Arg2:T13	
T14	Non-representable 294 381	Availability of tumor biopsy material extracted and preserved by the investigating site
